Ethalfluralin
Ethalfluralin is a dinitroaniline herbicide and microtubule inhibitor. Ethalfluralin blocks nuclear division and cytokinesis of parasites by inhibiting intranuclear spindle formation. Ethalfluralin activates the phosphorylation levels of NF-κB and P38 MAPK, inhibits the PI3K/AKT signaling pathway, impairs mitochondrial function, and induces apoptosis, endoplasmic reticulum stress, autophagy, and ROS production. Ethalfluralin is applicable to research related to toxoplasmosis.
For research use only. We do not sell to patients.
- CAS No.: 55283-68-6
- Formula: C13H14F3N3O4
- Molecular Weight:333.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HFF | IC50 |
0.26 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
0.65 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
1.4 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
1.6 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
1.7 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
13.5 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
19.5 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
2.1 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
2.5 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
24 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
28.7 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
4.2 μM
Compound: 5
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
In Vitro
Ethalfluralin (2-20 μM; 48 h) reduces the viability of pLE and pTr cells[1].
Ethalfluralin (20 μM; 48 h) inhibits the expression of the proliferation marker PCNA in pLE and pTr cells[1].
Ethalfluralin (20 μM; 4 h) impairs the migratory capacity of pLE and pTr cells[1].
Ethalfluralin (5-20 μM; 48 h) induces cell cycle arrest in pLE and pTr cells, resulting in an increase in the sub-G1 cell population and a decrease in the S-phase cell population[1].
Ethalfluralin (5-20 μM; 48 h) induces apoptotic cell death in pLE and pTr cells, increases the late apoptotic cell population in both cell lines, and elevates the early apoptotic cell population in pTr cells[1].
Ethalfluralin (5-20 μM; 48 h) reduces cytoplasmic calcium levels in pLE and pTr cells[1].
Ethalfluralin (5-20 μM; 48 h) reduces mitochondrial matrix calcium levels in pLE and pTr cells[1].
Ethalfluralin (5-20 μM; 48 h) disrupts the mitochondrial membrane potential of pLE and pTr cells[1].
Ethalfluralin (20 μM; 20 h) impairs mitochondrial respiratory function in pLE and pTr cells, reduces basal respiration, maximal respiration, spare respiratory capacity and ATP production in pLE cells, and decreases maximal respiration, spare respiratory capacity and ATP production in pTr cells[1].
Ethalfluralin (20 μM; 24 h) downregulates the mRNA expression of genes encoding subunits of mitochondrial respiratory complexes I-V in pLE and pTr cells[1].
Ethalfluralin (5-20 μM; 48 h) activates endoplasmic reticulum stress and autophagy pathways in pLE and pTr cells, upregulates the expression levels of GRP78, phosphorylated eIF2α, GADD153, phosphorylated ULK1 and phosphorylated P62, and promotes LC3B II/I conversion[1].
Ethalfluralin (5-20 μM; 48 h) activates the P38 MAPK and NF-κB signaling pathways, and inhibits the PI3K/AKT signaling pathway in pLE and pTr cells[1].
Ethalfluralin (20 μM; 48 h) impairs autophagic flux and reduces mitochondrial mass in pLE and pTr cells[1].
Ethalfluralin potently inhibits the replication of tachyzoites of Toxoplasma gondii RH strain in human primary foreskin fibroblasts, with an IC50 of 100 nM[3].
Ethalfluralin (0.5 μM; 36 h) exerts no significant inhibitory effect on the invasion of primary human foreskin fibroblasts by tachyzoites of Toxoplasma gondii RH strain, but causes severe morphological abnormalities in intracellular parasites[3].
Ethalfluralin (1 μM; 0-24 h) ablates the plaque-forming ability of tachyzoites of Toxoplasma gondii RH strain in primary human foreskin fibroblasts within 8-12 h, but has no effect on the viability of extracellular tachyzoites treated for 12 h[3].
Ethalfluralin (1 μM; 0-24 h) acts for up to 24 h but does not inhibit nucleic acid synthesis of tachyzoites of the Toxoplasma gondii RH strain in primary human foreskin fibroblasts, even though it completely abolishes parasite activity[3].
Ethalfluralin (1 μM; 20 h) blocks nuclear division of tachyzoites of the Toxoplasma gondii RH strain in primary human foreskin fibroblasts by inhibiting intranuclear spindle formation, while preserving their subpellicular microtubules and causing expansion of the endomembrane compartment[3].
Ethalfluralin (1 μM) inhibits the release of tachyzoites of Toxoplasma gondii RH strain induced by calcium ionophores in primary human foreskin fibroblasts, and simultaneously causes shrinkage of the vacuolar space and increased refractivity of treated parasites after ionophore treatment[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:porcine luminal epithelial (pLE) cells, porcine trophectoderm (pTr) cells
-
Concentration:2, 5, 10, 20 μM
-
Incubation Time:48 h
-
Result:Suppressed pLE cell viability to 42% and pTr cell viability to 43% relative to vehicle-treated cells at 20 μM.
-
Cell Line:porcine luminal epithelial (pLE) cells, porcine trophectoderm (pTr) cells
-
Concentration:20 μM
-
Incubation Time:48 h
-
Result:Markedly reduced relative green fluorescence (PCNA expression) in both pLE and pTr cells compared to vehicle-treated cells.
-
Cell Line:porcine luminal epithelial (pLE) cells, porcine trophectoderm (pTr) cells
-
Concentration:20 μM
-
Incubation Time:4 h
-
Result:Reduced wounded area closure to 9.1% in pLE cells and 10.9% in pTr cells, compared to 27.4% and 30% in vehicle-treated cells, respectively.
-
Cell Line:porcine luminal epithelial (pLE) cells, porcine trophectoderm (pTr) cells
-
Concentration:5, 10 and 20 μM
-
Incubation Time:48 h
-
Result:Increased the sub-G1 population up to 3.3-fold in pLE cells and 2.2-fold in pTr cells.
Decreased the S phase population by 46% in pLE cells and 63% in pTr cells relative to vehicle-treated cells.
-
Cell Line:porcine luminal epithelial (pLE) cells, porcine trophectoderm (pTr) cells
-
Concentration:5, 10 and 20 μM
-
Incubation Time:48 h
-
Result:Increased the late apoptotic cell population up to 2.7-fold in pLE cells at 20 μM.
Increased the early apoptotic population to 198% at 10 μM and 321% at 20 μM, and increased the late apoptotic population by over 2-fold in pTr cells.
-
Cell Line:porcine luminal epithelial (pLE) cells, porcine trophectoderm (pTr) cells
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Downregulated mRNA expression of all tested mitochondrial respiratory complex I-V subunit genes (including NDUFS3, SDHB, UQCRC2, MT-CO1, and MT-ATP6) in both pLE and pTr cells.
-
Cell Line:porcine luminal epithelial (pLE) cells, porcine trophectoderm (pTr) cells
-
Concentration:5, 10 and 20 μM
-
Incubation Time:48 h
-
Result:Increased GRP78 protein levels by 2.9-fold in pLE cells and 2.8-fold in pTr cells at 20 μM.
Increased phosphorylated eIF2α by 1.7-1.8-fold in pLE cells and up to 2-fold in pTr cells at 20 μM.
Increased GADD153 by 2.4-fold in pLE cells and up to 2-fold in pTr cells at 20 μM.
Increased phosphorylated ULK1, phosphorylated P62, and LC3B I to LC3B II conversion ratio by 2-4-fold in both cell lines at 20 μM.\nIncreased phosphorylated p38 MAPK by over 4-fold in pLE cells and 2.2-fold in pTr cells at 20 μM.
Increased phosphorylated NF-κB by over 2-fold in both cell lines at 20 μM.
Reduced phosphorylated AKT by almost half in both cell lines at 20 μM.
Reduced phosphorylated S6 in both cell lines at 20 μM.
-
Cell Line:porcine luminal epithelial (pLE) cells, porcine trophectoderm (pTr) cells
-
Concentration:20 μM (with 10 μM Chloroquine (HY-17589A) pretreatment for 3 h)
-
Incubation Time:48 h
-
Result:Markedly increased p-p62 levels in both cell lines, did not further increase LC3B II/I conversion ratio compared to chloroquine alone, and reduced mitochondrial mass significantly in pLE cells (with a similar trend in pTr cells).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type, fli1a:eGFP and flk1:eGFP transgenic lines[2]
-
Dosage:6 mg/L, 9 mg/L, 12 mg/L
-
Administration:aqueous immersion; daily continuous; 96 hours
-
Result:Reduced survival rate, hatching rate and heart rate.
Led to edema of the heart and yolk sac, shortened body length, and spinal cord deformity.
Induced cell apoptosis, oxidative stress and verification.
Inhibited of angiogenesis.
Chemical Information
-
CAS No. 55283-68-6
-
Molecular Weight 333.26
-
Formula C13H14F3N3O4
-
SMILES
O=[N+]([O-])C1=C(N(CC)CC(C)=C)C([N+]([O-])=O)=CC(C(F)(F)F)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
References
[1]. Ham J, et al. Ethalfluralin impairs implantation by aggravation of mitochondrial viability and function during early pregnancy. Environ Pollut. 2022;307:119495. [Content Brief]
[2]. Hong T, et al. Ethalfluralin induces developmental toxicity in zebrafish via oxidative stress and inflammation. Sci Total Environ. 2023;854:158780. [Content Brief]
[3]. Stokkermans TJ, et al. Inhibition of Toxoplasma gondii replication by dinitroaniline herbicides. Exp Parasitol. 1996;84(3):355-370. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)